Skip to main content Accessibility help
×
Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-25T05:01:15.221Z Has data issue: false hasContentIssue false

21 - Neonatal oncology

from Section VIII - Miscellaneous

Published online by Cambridge University Press:  05 February 2013

Pedro de Alarcón
Affiliation:
University of Illinois College of Medicine
Eric Werner
Affiliation:
Children's Hospital of the King's Daughters
Robert D. Christensen
Affiliation:
McKay-Dee Hospital, Utah
Get access

Summary

Introduction

Tumors in the neonatal period are rare (1). Several principles extend throughout the spectrum of neonatal tumors when compared with other tumors. Neonatal tumors are more often benign. If malignant, they are more difficult to treat and more likely to be genetic. Fetal circulation can change metastatic patterns of malignancies. In general, cancer is treated using surgery, radiation, and chemotherapy. However, in neonates, radiation is avoided and chemotherapy has increased morbidity and mortality. Additionally, neonatal tumors tend to be more primitive tumors that are less sensitive to chemotherapy. With the increasing use of prenatal ultrasound, more neonatal tumors are diagnosed prenatally, and perinatal treatment modifications can be made. This is especially important in large abdominal, oral, or cervical tumors. This chapter will review both malignant and benign tumors that occur in the newborn (Table 21.1). For malignant tumors, a basic overview, covering incidence, staging, differential diagnosis, and treatment, is included.

Epidemiology

Cancer in the newborn (defined for the purpose of this chapter as cancer diagnosed before one month of life) is a rare event. Cancers diagnosed in neonates make up only 1% of all cancers diagnosed in children under 15 years of age (2). Data from the Third National Cancer Survey (1961–71) reported the incidence of cancer in neonates being 36.5 per million live births, with 50% found on the first day of life (3). Data from the Surveillance, Epidemiology, and End Result program from 1973 to 1992 show the incidence of neonatal cancer is 26.8 per million live births (2).

Type
Chapter
Information
Neonatal Hematology
Pathogenesis, Diagnosis, and Management of Hematologic Problems
, pp. 369 - 384
Publisher: Cambridge University Press
Print publication year: 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Stevens, MC.Neonatal tumours. Arch Dis Child 1988;63(10 Spec No):1122–5.CrossRefGoogle ScholarPubMed
Gurney, JG, Ross, JA, Wall, DA, Bleyer, WA, Severson, RK, Robison, LL. Infant cancer in the US: histology-specific incidence and trends, 1973 to 1992. J Pediatr Hematol Oncol 1997;19:428–32.CrossRefGoogle Scholar
Bader, JL, Miller, RW. US cancer incidence and mortality in the first year of life. Am J Dis Child 1979;133:157–9.Google ScholarPubMed
Horner, MJ, Krapcho, M, Neyman, N, et al. (eds). SEER Cancer Statistics Review, 1975–2006, National Cancer Institute. Bethesda, MD, , based on November 2008 SEER data submission, posted to the SEER web site, 2009. [cited 2009 August 10]; Available from: .
Borch, K, Jacobsen, T, Olsen, JH, Hirsch, F, Hertz, H. Neonatal cancer in Denmark 1943–1985. Pediatr Hematol Oncol 1992;9:209–16.CrossRefGoogle ScholarPubMed
Parkes, SE, Muir, KR, Southern, L, Cameron, AH, Darbyshire, PJ, Stevens, MC. Neonatal tumours: a thirty-year population-based study. Med Pediatr Oncol 1994;22:309–17.CrossRefGoogle ScholarPubMed
Rennie, JM. Roberton’s Textbook of Neonatology. 4th edn. Edinburgh: Elsevier/Churchill Livingstone, 2005.Google Scholar
Campbell, AN, Chan, HS, O’Brien, A, Smith, CR, Becker, LE. Malignant tumours in the neonate. Arch Dis Child 1987;62:19–23.CrossRefGoogle ScholarPubMed
Rao, S, Azmy, A, Carachi, R. Neonatal tumours: a single-centre experience. Pediatr Surg Int 2002;18:306–9.Google ScholarPubMed
Isaacs, H, Jr. Congenital and neonatal malignant tumors. A 28-year experience at Children’s Hospital of Los Angeles. Am J Pediatr Hematol Oncol 1987;9:121–9.CrossRefGoogle ScholarPubMed
Isaacs, H, Jr. Perinatal (fetal and neonatal) germ cell tumors. J Pediatr Surg 2004;39:1003–13.CrossRefGoogle ScholarPubMed
Pizzo, PA, Poplack, DG. Principles and Practice of Pediatric Oncology. 5th edn. Philadelphia: Lippincott Williams & Wilkins, 2006.Google Scholar
Schneider, DT, Calaminus, G, Koch, S, et al. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood Cancer 2004;42:169–75.CrossRefGoogle ScholarPubMed
Keeling, J, Khong, TY. Fetal and Neonatal Pathology. 4th edn. New York; London: Springer, 2007.CrossRefGoogle Scholar
Kumar, B, Sharma, SB. Neonatal oral tumors: congenital epulis and epignathus. J Pediatr Surg 2008;43:e9–11.Google ScholarPubMed
Celik, M, Akkaya, H, Arda, IS, Hicsonmez, A. Congenital teratoma of the tongue: a case report and review of the literature. J Pediatr Surg 2006;41:e25–8.CrossRefGoogle ScholarPubMed
Isaacs, H, Jr. Fetal and neonatal cardiac tumors. Pediatr Cardiol 2004;25:252–73.CrossRefGoogle ScholarPubMed
Huddart, SN, Mann, JR, Robinson, K, et al. Sacrococcygeal teratomas: the UK Children’s Cancer Study Group’s experience. I. Neonatal Pediatr Surg Int 2003;19:47–51.Google ScholarPubMed
Rescorla, FJ, Sawin, RS, Coran, AG, Dillon, PW, Azizkhan, RG. Long-term outcome for infants and children with sacrococcygeal teratoma: a report from the Children’s Cancer Group. J Pediatr Surg 1998;33:171–6.CrossRefGoogle Scholar
Derikx, JP, De Backer, A, van de Schoot, L, et al. Factors associated with recurrence and metastasis in sacrococcygeal teratoma. Br J Surg 2006;93:1543–8.CrossRefGoogle ScholarPubMed
Swamy, R, Embleton, N, Hale, J.Sacrococcygeal teratoma over two decades: birth prevalence, prenatal diagnosis and clinical outcomes. Prenat Diagn 2008;28:1048–51.CrossRefGoogle ScholarPubMed
Gopal, M, Turnpenny, PD, Spicer, R. Hereditary sacrococcygeal teratoma – not the same as its sporadic counterpart!Eur J Pediatr Surg 2007;17:214–16.CrossRefGoogle Scholar
Isaacs, H, Jr. I. Perinatal brain tumors: a review of 250 cases. Pediatr Neurol 2002;27:249–61.CrossRefGoogle ScholarPubMed
Mazewski, CM, Hudgins, RJ, Reisner, A, Geyer, JR. Neonatal brain tumors: a review. Semin Perinatol 1999;23:286–98.CrossRefGoogle ScholarPubMed
Azizkhan, RG, Haase, GM, Applebaum, H, et al. Diagnosis, management, and outcome of cervicofacial teratomas in neonates: a Children’s Cancer Group study. J Pediatr Surg 1995;30:312–16.CrossRefGoogle Scholar
Levy, DA, Kay, R, Elder, JS. Neonatal testis tumors: a review of the Prepubertal Testis Tumor Registry. J Urol 1994;151:715–17.CrossRefGoogle ScholarPubMed
Coppes, MJ, Rackley, R, Kay, R. Primary testicular and paratesticular tumors of childhood. Med Pediatr Oncol 1994;22:329–40.CrossRefGoogle ScholarPubMed
Blohm, ME, Gobel, U. Unexplained anaemia and failure to thrive as initial symptoms of infantile choriocarcinoma: a review. Eur J Pediatr 2004;163:1–6.CrossRefGoogle ScholarPubMed
Kenney, LB, Miller, BA, Ries, LA, Nicholson, HS, Byrne, J, Reaman, GH. Increased incidence of cancer in infants in the US: 1980–1990. Cancer 1998;82:1396–400.3.0.CO;2-0>CrossRefGoogle Scholar
Francis, JS, Sybert, VP, Benjamin, DR. Congenital monocytic leukemia: report of a case with cutaneous involvement, and review of the literature. Pediatr Dermatol 1989;6:306–11.CrossRefGoogle ScholarPubMed
Zweidler-McKay, PA, Hilden, JM. The ABCs of infant leukemia. Curr Probl Pediatr Adolesc Health Care 2008;38:78–94.CrossRefGoogle ScholarPubMed
Dinulos, JG, Hawkins, DS, Clark, BS, Francis, JS. Spontaneous remission of congenital leukemia. J Pediatr 1997;131:300–3.CrossRefGoogle ScholarPubMed
Hilden, JM, Dinndorf, PA, Meerbaum, SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children’s Oncology Group. Blood 2006;108:441–51.CrossRefGoogle ScholarPubMed
Heerema, NA, Sather, HN, Ge, J, Arthur, DC, et al. Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) – a report of the Children’s Cancer Group. Leukemia 1999;13:679–86.CrossRefGoogle Scholar
Massey, GV. Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer 2005;44:29–32.CrossRefGoogle ScholarPubMed
Zipursky, A, Rose, T, Skidmore, M, Thorner, P, Doyle, J. Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatr Hematol Oncol 1996;13:81–7.CrossRefGoogle ScholarPubMed
Schwab, M, Niemeyer, C, Schwarzer, U. Down syndrome, transient myeloproliferative disorder, and infantile liver fibrosis. Med Pediatr Oncol 1998;31:159–65.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Al-Kasim, F, Doyle, JJ, Massey, GV, Weinstein, HJ, Zipursky, A. Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group Study. J Pediatr Hematol Oncol 2002;24:9–13.CrossRefGoogle ScholarPubMed
Hayashi, Y, Eguchi, M, Sugita, K, et al. Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down’s syndrome. Blood 1988;72:15–23.Google ScholarPubMed
Gopal, M, Chahal, G, Al-Rifai, Z, Eradi, B, Ninan, G, Nour, S. Infantile myofibromatosis. Pediatr Surg Int 2008;24:287–91.CrossRefGoogle ScholarPubMed
Hosalkar, HS, Fox, EJ, Delaney, T, Torbert, JT, Ogilvie, CM, Lackman, RD. Desmoid tumors and current status of management. Orthop Clin North Am 2006;37:53–63.CrossRefGoogle ScholarPubMed
Grenier, N, Liang, C, Capaldi, L, et al. A range of histologic findings in infantile digital fibromatosis. Pediatr Dermatol 2008;25:72–5.CrossRefGoogle ScholarPubMed
Ferrari, A, Casanova, M, Bisogno, G, et al. Rhabdomyosarcoma in infants younger than one year old: a report from the Italian Cooperative Group. Cancer 2003;97:2597–604.CrossRefGoogle ScholarPubMed
Lobe, TE, Wiener, ES, Hays, DM, et al. Neonatal rhabdomyosarcoma: the IRS experience. J Pediatr Surg 1994;29:1167–70.CrossRefGoogle ScholarPubMed
Barr, FG. Molecular genetics and pathogenesis of rhabdomyosarcoma. J Pediatr Hematol Oncol 1997;19:483–91.CrossRefGoogle ScholarPubMed
Meza, JL, Anderson, J, Pappo, AS, Meyer, WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children’s Oncology Group. J Clin Oncol 2006;24:3844–51.CrossRefGoogle ScholarPubMed
Breneman, JC, Lyden, E, Pappo, AS, et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the Intergroup Rhabdomyosarcoma Study IV. J Clin Oncol 2003;21:78–84.CrossRefGoogle ScholarPubMed
Russell, H, Hicks, MJ, Bertuch, AA, Chintagumpala, M. Infantile fibrosarcoma: clinical and histologic responses to cytotoxic chemotherapy. Pediatr Blood Cancer 2009;53:23–7.CrossRefGoogle ScholarPubMed
Knezevich, SR, McFadden, DE, Tao, W, Lim, JF, Sorensen, PH. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 1998;18:184–7.CrossRefGoogle ScholarPubMed
Loh, ML, Ahn, P, Perez-Atayde, AR, Gebhardt, MC, Shamberger, RC, Grier, HE. Treatment of infantile fibrosarcoma with chemotherapy and surgery: results from the Dana-Farber Cancer Institute and Children’s Hospital, Boston. J Pediatr Hematol Oncol 2002;24:722–6.CrossRefGoogle ScholarPubMed
Kynaston, JA, Malcolm, AJ, Craft, AW, et al. Chemotherapy in the management of infantile fibrosarcoma. Med Pediatr Oncol 1993;21:488–93.CrossRefGoogle ScholarPubMed
Jacobs, AH, Walton, RG. The incidence of birthmarks in the neonate. Pediatrics 1976;58:218–22.Google ScholarPubMed
Dinehart, SM, Kincannon, J, Geronemus, R. Hemangiomas: evaluation and treatment. Dermatol Surg 2001;27:475–85.Google ScholarPubMed
Trobs, RB, Mader, E, Friedrich, T, Bennek, J. Oral tumors and tumor-like lesions in infants and children. Pediatr Surg Int 2003;19:639–45.CrossRefGoogle ScholarPubMed
Beil, CM, Keberle, M. Oral and oropharyngeal tumors. Eur J Radiol 2008;66:448–59.CrossRefGoogle ScholarPubMed
Metry, DW, Hebert, AA. Benign cutaneous vascular tumors of infancy: when to worry, what to do. Arch Dermatol 2000;136:905–14.CrossRefGoogle ScholarPubMed
von Schweinitz, D. Neonatal liver tumours. Semin Neonatol 2003;8:403–10.CrossRefGoogle ScholarPubMed
Ezekowitz, RA, Mulliken, JB, Folkman, J.Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 1992;326:1456–63.CrossRefGoogle ScholarPubMed
Barlow, CF, Priebe, CJ, Mulliken, JB, et al. Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998;132:527–30.CrossRefGoogle ScholarPubMed
Michaud, AP, Bauman, NM, Burke, DK, Manaligod, JM, Smith, RJ. Spastic diplegia and other motor disturbances in infants receiving interferon-alpha. Laryngoscope 2004;114:1231–6.CrossRefGoogle ScholarPubMed
Isaacs, H, Jr. Fetal and neonatal histiocytoses. Pediatr Blood Cancer 2006;47:123–9.CrossRefGoogle ScholarPubMed
Huang, F, Arceci, R. The histiocytoses of infancy. Semin Perinatol 1999;23:319–31.Google ScholarPubMed
Minkov, M, Prosch, H, Steiner, M, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer 2005;45:802–7.CrossRefGoogle ScholarPubMed
Weitzman, S, Egeler, RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr 2008;20:23–9.CrossRefGoogle ScholarPubMed
Minkov, M, Grols, N, McClain, K, et al. Langerhans cell histiocytosis: Histiocyte Society Evaluation and Treatment Guidelines. 2009 cited; Available from: . .
Stein, SL, Paller, AS, Haut, PR, Mancini, AJ. Langerhans cell histiocytosis presenting in the neonatal period: a retrospective case series. Arch Pediatr Adolesc Med 2001;155:778–83.CrossRefGoogle ScholarPubMed
Henter, JI, Horne, A, Arico, M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007;48:124–31.CrossRefGoogle ScholarPubMed
Lafay-Cousin, L, Strother, D. Current treatment approaches for infants with malignant central nervous system tumors. Oncologist 2009;14:433–44.CrossRefGoogle ScholarPubMed
Gonzalez, KD, Noltner, KA, Buzin, CH, et al. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:1250–6.CrossRefGoogle ScholarPubMed
Isaacs, H, Jr. II. Perinatal brain tumors: a review of 250 cases. Pediatr Neurol 2002;27:333–42.CrossRefGoogle ScholarPubMed
Abramson, DH, Du, TT, Beaverson, KL. (Neonatal) retinoblastoma in the first month of life. Arch Ophthalmol 2002;120:738–42.CrossRefGoogle ScholarPubMed
Chintagumpala, M, Chevez-Barrios, P, Paysse, EA, Plon, SE, Hurwitz, R. Retinoblastoma: review of current management. Oncologist 2007;12:1237–46.CrossRefGoogle ScholarPubMed
Isaacs, H. Tumors of the Fetus and Infant: An Atlas. New York: Springer, 2002.Google Scholar
Isaacs, H, Jr. Fetal and neonatal hepatic tumors. J Pediatr Surg 2007;42:1797–803.CrossRefGoogle ScholarPubMed
Reynolds, P, Urayama, KY, Von Behren, J, Feusner, J. Birth characteristics and hepatoblastoma risk in young children. Cancer 2004;100:1070–6.CrossRefGoogle ScholarPubMed
Linabery, AM, Ross, JA. Trends in childhood cancer incidence in the US (1992–2004). Cancer 2008;112:416–32.CrossRefGoogle Scholar
Herzog, CE, Andrassy, RJ, Eftekhari, F. Childhood cancers: hepatoblastoma. Oncologist 2000;5:445–53.CrossRefGoogle ScholarPubMed
Glick, RD, Hicks, MJ, Nuchtern, JG, Wesson, DE, Olutoye, OO, Cass, DL. Renal tumors in infants less than 6 months of age. J Pediatr Surg 2004;39:522–5.Google ScholarPubMed
Chandler, JC, Gauderer, MW. The neonate with an abdominal mass. Pediatr Clin North Am 2004;51:979–97, ix.CrossRefGoogle ScholarPubMed
Isaacs, H, Jr. Fetal and neonatal renal tumors. J Pediatr Surg 2008;43:1587–95.CrossRefGoogle ScholarPubMed
van den Heuvel-Eibrink, MM, Grundy, P, Graf, N, et al. Characteristics and survival of 750 children diagnosed with a renal tumor in the first seven months of life: A collaborative study by the SIOP/GPOH/SFOP, NWTSG, and UKCCSG Wilms tumor study groups. Pediatr Blood Cancer 2008;50:1130–4.CrossRefGoogle ScholarPubMed
Patel, Y, Mitchell, CD, Hitchcock, RJ. Use of sarcoma-based chemotherapy in a case of congenital mesoblastic nephroma with liver metastases. Urology 2003;61:1260.CrossRefGoogle Scholar
Ritchey, ML, Azizkhan, RG, Beckwith, JB, Hrabovsky, EE, Haase, GM. Neonatal Wilms tumor. J Pediatr Surg 1995;30:856–9.CrossRefGoogle ScholarPubMed
Green, DM, Breslow, NE, Beckwith, JB, et al. Treatment with nephrectomy only for small, stage I/favorable histology Wilms’ tumor: a report from the National Wilms’ Tumor Study Group. J Clin Oncol 2001;19:3719–24.CrossRefGoogle Scholar
Amar, AM, Tomlinson, G, Green, DM, Breslow, NE, de Alarcon, PA. Clinical presentation of rhabdoid tumors of the kidney. J Pediatr Hematol Oncol 2001;23:105–8.CrossRefGoogle ScholarPubMed
Nadler, EP, Barksdale, EM. Adrenal masses in the newborn. Semin Pediatr Surg 2000;9:156–64.CrossRefGoogle ScholarPubMed
Felc, Z. Ultrasound in screening for neonatal adrenal hemorrhage. Am J Perinatol 1995;12:363–6.Google ScholarPubMed
Curtis, MR, Mooney, DP, Vaccaro, TJ, et al. Prenatal ultrasound characterization of the suprarenal mass: distinction between neuroblastoma and subdiaphragmatic extralobar pulmonary sequestration. J Ultrasound Med 1997;16:75–83.CrossRefGoogle ScholarPubMed
Moppett, J, Haddadin, I, Foot, AB. Neonatal neuroblastoma. Arch Dis Child Fetal Neonatal Ed 1999;81:F134–7.CrossRefGoogle ScholarPubMed
Isaacs, H, Jr. Fetal and neonatal neuroblastoma: retrospective review of 271 cases. Fetal Pediatr Pathol 2007;26:177–84.CrossRefGoogle ScholarPubMed
George, RE, Lipshultz, SE, Lipsitz, SR, Colan, SD, Diller, L. Association between congenital cardiovascular malformations and neuroblastoma. J Pediatr 2004;144:444–8.CrossRefGoogle ScholarPubMed
Tuchman, M, Ramnaraine, ML, Woods, WG, Krivit, W. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987;79:203–5.Google Scholar
Maris, JM, Hogarty, MD, Bagatell, R, Cohn, SL. Neuroblastoma. Lancet 2007;369:2106–20.CrossRefGoogle ScholarPubMed
Brodeur, GM, Pritchard, J, Berthold, F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–77.CrossRefGoogle ScholarPubMed
Matthay, KK, Perez, C, Seeger, RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 1998;16:1256–64.CrossRefGoogle ScholarPubMed
Schmidt, ML, Lukens, JN, Seeger, RC, et al. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children’s Cancer Group study. J Clin Oncol 2000;18:1260–8.CrossRefGoogle ScholarPubMed
Nickerson, HJ, Matthay, KK, Seeger, RC, et al. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children’s Cancer Group study. J Clin Oncol 2000;18:477–86.CrossRefGoogle ScholarPubMed
Warner, A. Drug use in the neonate: interrelationships of pharmacokinetics, toxicity, and biochemical maturity. Clin Chem 1986;32:721–7.Google ScholarPubMed
Weitzman, S, Grant, R. Neonatal oncology: diagnostic and therapeutic dilemmas. Semin Perinatol 1997;21:102–11.CrossRefGoogle ScholarPubMed
Littman, P, D’Angio, GJ. Radiation therapy in the neonate. Am J Pediatr Hematol Oncol 1981;3:279–85.Google ScholarPubMed
Mundshau, G;Gurbuxani, S, Gamis, AS, et al. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 2003;101:4298–4300.CrossRefGoogle Scholar
Klusmann, JH, Creutzig, U, Zimmerman, M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 2008;111:2991–2998.CrossRefGoogle ScholarPubMed
Gamis, ASM, Alonzo, TAM, Gerbing, RBM, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood 2011;118:6752–6759.CrossRefGoogle ScholarPubMed
Massey, GVM, Zipursky, AM, Chang, MN, et al. A prospective study of the natural histoy of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group Study POG-9481. Blood 2006;107:4606–4613.CrossRefGoogle Scholar
Pine, SR, Guo, Q, Yin, C, et al. Incidence and clinical implications of GATA1 mutations in newborns with Down Syndrome. Blood 2007;110:2128–2131.CrossRefGoogle ScholarPubMed
Zipursky, A, Brown, E, Christensen, H, et al. Leukemia and/ or myeloproiferative syndrome in neonates with Down Syndrome. Semin Perinatol 1997;21:97–101.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×